多西他赛不同联合用药方案周剂量治疗晚期胃癌的研究
|
摘要
目的探讨多西他赛不同联合用药方案周剂量治疗晚期胃癌的临床疗效及安全性。方法纳入我院2014年5月至2016年5月收治的胃癌患者70例,随机分为观察组(O组)及对照组(C组)各35例。C组治疗方案为多西他赛+顺铂,O组治疗方案为多西他赛+奥沙利铂。其中多西他赛剂量为35 mg/m~2,顺铂剂量为60 mg/m~2,奥沙利铂剂量为120 mg/m~2,分别于第1天、8天,静脉滴注,21天为一个化疗周期,共4个周期。比较两组化疗效果和化疗期间不良反应、1年总生存率及肿瘤无进展生存率。结果 O组和C组总有效率分别为68. 57%和60%,两种化疗方案的总体疗效和总有效率比较,差异均无统计学意义(P> 0. 05),O组中位生存时间(10. 34±0. 40)月,C组中位生存时间(9. 77±0. 59)月。两组间中位无进展生存时间和中位生存时间比较,差异均无统计学意义(P> 0. 05)。O组不良反应总发生率低于C组,差异有统计学意义(P <0. 05)。结论多西他赛联合奥沙利铂治疗晚期胃癌疗效肯定,较多西他赛联合顺铂的安全性更高。
Objective To evaluate the efficacy and safety of docetaxel combined with weekly regimen in the treatment of advanced gastric cancer.Methods Seventy patients with gastric cancer admitted to our hospital from May 2014 to May 2016 were randomly divided into observation or control group,35 in each group.The control group was treated with docetaxel + cisplatin and the observation group was treated with docetaxel + oxaliplatin.The doses of docetaxel,cisplatin and oxaliplatin were 35 mg/m~2,60 mg/m~2 and 120 mg/m~2,respectively.The drugs were administrated with intravenous drip on the first day and the 8 th day.The chemotherapy cycle was 21 days and all patients underwent 4 cycles.The effects of chemotherapy and adverse reactions during chemotherapy,1-year overall survival rate and progression free survival rate were compared between the two groups.Results The total effective rates of the observation group and the control group were 68. 57% and 60%,respectively.The difference was not significant between the two groups( P > 0. 05).The median survival time in the observation group was( 10. 34 ± 0. 40) months and( 9. 77 ± 0. 59) months in the control group.There were no significant difference in the median progression free survival rate and median survival time between the two groups( P > 0. 05).The total incidence of adverse reactions was lower in the observation group than that in the control group( P < 0. 05).Conclusion The docetaxel combined with oxaliplatin is effective in the treatment of advanced gastric cancer,and it has better safety than docetaxel plus cisplatin.
Objective To evaluate the efficacy and safety of docetaxel combined with weekly regimen in the treatment of advanced gastric cancer.Methods Seventy patients with gastric cancer admitted to our hospital from May 2014 to May 2016 were randomly divided into observation or control group,35 in each group.The control group was treated with docetaxel + cisplatin and the observation group was treated with docetaxel + oxaliplatin.The doses of docetaxel,cisplatin and oxaliplatin were 35 mg/m~2,60 mg/m~2 and 120 mg/m~2,respectively.The drugs were administrated with intravenous drip on the first day and the 8 th day.The chemotherapy cycle was 21 days and all patients underwent 4 cycles.The effects of chemotherapy and adverse reactions during chemotherapy,1-year overall survival rate and progression free survival rate were compared between the two groups.Results The total effective rates of the observation group and the control group were 68. 57% and 60%,respectively.The difference was not significant between the two groups( P > 0. 05).The median survival time in the observation group was( 10. 34 ± 0. 40) months and( 9. 77 ± 0. 59) months in the control group.There were no significant difference in the median progression free survival rate and median survival time between the two groups( P > 0. 05).The total incidence of adverse reactions was lower in the observation group than that in the control group( P < 0. 05).Conclusion The docetaxel combined with oxaliplatin is effective in the treatment of advanced gastric cancer,and it has better safety than docetaxel plus cisplatin.
引文
[1]胡林,李昌荣,李红浪.胃全系膜切除在胃癌根治性手术中的应用进展[J].中华消化外科杂志,2015,14(3):250-252.
[2]王涛,赵磊,李榆,等.周剂量多西他赛联合顺铂与周剂量多西他赛联合奥沙利铂治疗晚期胃癌的临床研究[J].中国癌症杂志,2015,25(2):150-154.
[3]方庆丰,周正仕.多西他赛联合替吉奥治疗老年性晚期胃癌的疗效与安全性[J].中国临床药理学杂志,2013,29(7):494-495.
[4]朱尧武,杨宇飞,郝迎旭,等.晚期胃癌中医综合疗效标准模型的构建[J].辽宁中医杂志,2013,9(3):457-460.
[5]Kim ER,Lee H,Min B,et al.Effect of rescue surgery after non-curative endoscopic resection of early gastric cancer[J].British Journal of Surgery,2015,102(11):1394-401.
[6]陈瑞红,于红刚.中晚期胃癌介入化疗的临床研究[J].中华试验外科杂志,2015,32(3):481-482.
[7]黄晋熙,王程虎,原伟伟,等.胃癌术后替吉奥联合多西他赛及奥沙利铂辅助化疗效果的研究[J].中国临床药理学杂志,2013,19(10):742-744.
[8]刘林,杨新辉,王海江,等.多西他赛联合奥沙利铂及替吉奥治疗进展期胃癌的疗效及对围手术期影响[J].中国肿瘤临床,2013,40(13):788-791.
[9]卓小丽,谢贤和,李诗运,等.周剂量多西他赛联合卡培他滨与XELOX方案在晚期胃癌的疗效比较[J].海南医学院学报,2011,19(11):1497-1499.
[10]武海涛,姬忠贺,张倩,等.洛铂联合多西他赛行肿瘤细胞减灭术加腹腔热灌注化疗治疗同时性胃癌腹膜癌[J].中国肿瘤临床,2016,43(4):146-151.
[11]韩晓娜,曲颜丽,唐勇,等.晚期胃癌DCF方案与ECF方案治疗的Meta分析[J].肿瘤防治研究,2014,41(10):1102-1106.
[12]樊卫飞,王峻,孟丽娟,等.替吉奥联合奥沙利铂对比替吉奥联合顺铂方案一线治疗老年晚期胃癌的临床研究[J].临床肿瘤学杂志,2013,18(1):50-53.
[13]徐全晓,常占国,张晓冬,等.CIK细胞联合多西他赛、奥沙利铂、替吉奥治疗晚期胃癌的疗效观察[J].中国肿瘤生物治疗杂志,2015,22(3):381-384.
[14]王妹兴,陶莉,成少华,等.周剂量多西他赛联合顺铂和低剂量氟尿嘧啶治疗晚期胃癌的临床观察[J].中国肿瘤临床与康复杂志,2013,18(3):229-231.
[15]李俊,何樱,熊海林,等.周剂量多西他赛联合卡培他滨治疗晚期胃癌的疗效观察[J].肿瘤药学杂志,2012,2(4):302-304.
[16]黄晋熙,杨铁军,王程虎,等.多西他赛联合奥沙利铂及替吉奥新辅助化疗对局部晚期胃上部癌的疗效及安全性评价[J].中国临床药理学杂志,2015,31(9):722-724.
[2]王涛,赵磊,李榆,等.周剂量多西他赛联合顺铂与周剂量多西他赛联合奥沙利铂治疗晚期胃癌的临床研究[J].中国癌症杂志,2015,25(2):150-154.
[3]方庆丰,周正仕.多西他赛联合替吉奥治疗老年性晚期胃癌的疗效与安全性[J].中国临床药理学杂志,2013,29(7):494-495.
[4]朱尧武,杨宇飞,郝迎旭,等.晚期胃癌中医综合疗效标准模型的构建[J].辽宁中医杂志,2013,9(3):457-460.
[5]Kim ER,Lee H,Min B,et al.Effect of rescue surgery after non-curative endoscopic resection of early gastric cancer[J].British Journal of Surgery,2015,102(11):1394-401.
[6]陈瑞红,于红刚.中晚期胃癌介入化疗的临床研究[J].中华试验外科杂志,2015,32(3):481-482.
[7]黄晋熙,王程虎,原伟伟,等.胃癌术后替吉奥联合多西他赛及奥沙利铂辅助化疗效果的研究[J].中国临床药理学杂志,2013,19(10):742-744.
[8]刘林,杨新辉,王海江,等.多西他赛联合奥沙利铂及替吉奥治疗进展期胃癌的疗效及对围手术期影响[J].中国肿瘤临床,2013,40(13):788-791.
[9]卓小丽,谢贤和,李诗运,等.周剂量多西他赛联合卡培他滨与XELOX方案在晚期胃癌的疗效比较[J].海南医学院学报,2011,19(11):1497-1499.
[10]武海涛,姬忠贺,张倩,等.洛铂联合多西他赛行肿瘤细胞减灭术加腹腔热灌注化疗治疗同时性胃癌腹膜癌[J].中国肿瘤临床,2016,43(4):146-151.
[11]韩晓娜,曲颜丽,唐勇,等.晚期胃癌DCF方案与ECF方案治疗的Meta分析[J].肿瘤防治研究,2014,41(10):1102-1106.
[12]樊卫飞,王峻,孟丽娟,等.替吉奥联合奥沙利铂对比替吉奥联合顺铂方案一线治疗老年晚期胃癌的临床研究[J].临床肿瘤学杂志,2013,18(1):50-53.
[13]徐全晓,常占国,张晓冬,等.CIK细胞联合多西他赛、奥沙利铂、替吉奥治疗晚期胃癌的疗效观察[J].中国肿瘤生物治疗杂志,2015,22(3):381-384.
[14]王妹兴,陶莉,成少华,等.周剂量多西他赛联合顺铂和低剂量氟尿嘧啶治疗晚期胃癌的临床观察[J].中国肿瘤临床与康复杂志,2013,18(3):229-231.
[15]李俊,何樱,熊海林,等.周剂量多西他赛联合卡培他滨治疗晚期胃癌的疗效观察[J].肿瘤药学杂志,2012,2(4):302-304.
[16]黄晋熙,杨铁军,王程虎,等.多西他赛联合奥沙利铂及替吉奥新辅助化疗对局部晚期胃上部癌的疗效及安全性评价[J].中国临床药理学杂志,2015,31(9):722-724.